• Universal MRD solution unbounded to baseline sample availability
• MRD detection with ability to capture new actionable mutations undetected at baseline
• Designed to monitor cancer treatment response or detect cancer recurrence
• Adopted by leading biopharmas in global clinical trials
Whole blood
Plasma
Urine
30-60 ng of cfDNA
10 days
Technical specifications
PredicineALERT™ helps you detect novel acquired alterations that are missed from other MRD tests. Plasma-level VAF limit of detection (LOD) for conventional technologies are at 0.01%, which is 2X lower than the 0.005% VAF LOD achieved with PredicineALERT™.
MRD detection with PredicineALERT™ is different from conventional MRD assays because it is not limited to baseline samples. If available, baseline can be assessed using patient’s plasma, urine or tissue. If baseline sample is unavailable, monitoring the recurrence or progression of cancer can be achieved with a simple blood draw with our tissue-agnostic approach.
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.
If you have any questions or need assistance, complete this form and we will respond within 24 hours.